Gadoversetamide
ApprovedCompleted 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Pathological Processes
Conditions
Pathological Processes
Trial Timeline
May 1, 2002 → Dec 1, 2003
NCT ID
NCT01092754About Gadoversetamide
Gadoversetamide is a approved stage product being developed by Guerbet for Pathological Processes. The current trial status is completed. This product is registered under clinical trial identifier NCT01092754. Target conditions include Pathological Processes.
Hype Score Breakdown
Clinical
30
Activity
20
Company
2
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01092754 | Approved | Completed |
Competing Products
4 competing products in Pathological Processes
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| olanzapine + sugar pill | Eli Lilly | Phase 3 | 77 |
| Ranibizumab + Verteporfin PDT + Sham Ranibizumab + Sham verteporfin PDT | Novartis | Phase 3 | 77 |
| VEGF Trap-Eye (BAY86-5321) | Regeneron Pharmaceuticals | Phase 3 | 76 |
| Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/mL thrombin and synthetic aprotinin (FS VH S/D 500 s-apr) | Baxter | Phase 2 | 49 |